» Articles » PMID: 8260377

Serum Lactate Dehydrogenase Level As a Prognostic Factor in Hodgkin's Disease

Overview
Journal Br J Cancer
Specialty Oncology
Date 1993 Dec 1
PMID 8260377
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The efficacy of currently available treatments for Hodgkin's disease (HD) has led to a substantial modification in the prognosis of this disease; nevertheless there is still a group of patients that cannot be cured with conventional treatments and who will be candidates for alternative therapy. In the present work we analysed the prognostic influence of the most relevant clinico-biological characteristics of HD in a consecutive series of 137 patients diagnosed and treated in a single institution. Univariate analyses identified six variables with significant prognostic influence, both on achieving complete remission (CR) and overall survival (OS); LDH > 320 U ml-1, age > 45 years, stages IIB, III and IV, extranodal involvement, alkaline phosphatase > 190 UI dl and ESR > 40 mm h. In addition, Hb < 12.5 gr dl-1 and abdominal disease were statistically relevant for CR while a poor performance score (ECOG > or = 2) affected a lower survival. In the multivariate analysis only LDH, age and the clinical stage retained a significant prognostic influence for achieving CR, while the two first factors above, together with performance status were the variables with independent prognostic value with respect to OS. Moreover, only LDH > 320 U ml-1 had prognostic influence in the probability of relapse and disease free survival (DFS), both in the univariate and multivariate analyses. According to the three independent factors obtained in the multivariate analysis for CR (LDH, age and stage) a predictive model was established that allows the stratification of patients into two prognostic groups: one with poor prognosis that includes patients with the three adverse prognostic factors, or two if one of them was elevated LDH, and the other with good prognosis that includes the remaining patients. This model was also able to separate two independent groups of patients with respect to OS and to DFS. In conclusion, the present study shows that LDH is one of the most important prognostic factors in HD.

Citing Articles

Deciphering the Metabolic Basis and Molecular Circuitry of the Warburg Paradox in Lymphoma.

Ravi D, Kritharis A, Evens A Cancers (Basel). 2024; 16(21).

PMID: 39518046 PMC: 11545614. DOI: 10.3390/cancers16213606.


A positive correlation between serum lactate dehydrogenase level and in-hospital mortality in ICU sepsis patients: evidence from two large databases.

Yu H, Yang Q, Qian Y, Luo S, Kong T, Yang G Eur J Med Res. 2024; 29(1):525.

PMID: 39487549 PMC: 11531135. DOI: 10.1186/s40001-024-02071-4.


Biochemical risk factors and outcomes of acute promyelocytic leukemia patients with thrombotic events: a matched pair analysis.

Song X, Chi C, Gao W, Sun W, Liu Y, Zhang X J Thromb Thrombolysis. 2024; 57(5):828-841.

PMID: 38700714 DOI: 10.1007/s11239-024-02988-x.


Multivariate prognostic index and triplet regimen efficacy predictive index in locally advanced and metastatic gastric cancer: pooled analysis from three clinical trials using individual patient data.

Feng W, Zhao X, He Y, Huang M, Chen Z, Wang Y Ther Adv Med Oncol. 2024; 16:17588359241233982.

PMID: 38420603 PMC: 10901054. DOI: 10.1177/17588359241233982.


The Burden of COVID-19 in Adult Patients With Hematological Malignancies: A Single-center Experience After the Implementation of Mass-vaccination Programs Against SARS-CoV-2.

Rapti V, Papanikolopoulou A, Kokkotis G, Livanou M, Alexiou P, Pechlivanidou E In Vivo. 2023; 37(6):2743-2754.

PMID: 37905643 PMC: 10621438. DOI: 10.21873/invivo.13385.


References
1.
Gribben J, Linch D, Singer C, McMillan A, Jarrett M, Goldstone A . Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989; 73(1):340-4. View

2.
Specht L, Nissen N . Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol. 1988; 41(4):359-67. DOI: 10.1111/j.1600-0609.1988.tb00210.x. View

3.
Lister T, Crowther D, Sutcliffe S, Glatstein E, Canellos G, Young R . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989; 7(11):1630-6. DOI: 10.1200/JCO.1989.7.11.1630. View

4.
Straus D, Gaynor J, Myers J, Merke D, Caravelli J, Chapman D . Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990; 8(7):1173-86. DOI: 10.1200/JCO.1990.8.7.1173. View

5.
Villamor N, Reverter J, Marti J, Montserrat E, Rozman C . Clinical features and response to treatment of infradiaphragmatic Hodgkin's disease. Eur J Haematol. 1991; 46(1):38-41. DOI: 10.1111/j.1600-0609.1991.tb00511.x. View